MiR-520f acts as a biomarker for the diagnosis of lung cancer

Abstract

Lung cancer is a malignant tumor with high morbidity and mortality. Early diagnosis remains a great challenge for the cancer. In this study, we aimed to explore diagnostic performance of serum microRNA-520f ( miR-520f ) in lung cancer. Serum specimens were collected from 139 lung cancer patients and 76 healthy volunteers. Relative expression level of serum miR-520f was detected adopting quantitative real-time polymerase chain reaction (qRT-PCR). Chi-square test was applied to evaluate the association of miR-520f with clinical parameters of the patients. Additionally, receiver operating characteristic (ROC) analysis was performed to evaluate diagnostic value of miR-520f in lung cancer. Serum miR-520f was down-regulated in lung cancer patients compared with healthy group ( P <.001). Moreover, the expression of miR-520f was significantly associated with advanced TNM stage ( P = .031) and metastasis ( P = .002). The area under the curve (AUC) value of ROC curve was 0.888, suggesting that miR-520f could be a diagnostic biomarker for lung cancer. The cut-off value of serum miR-520f for lung cancer diagnosis was 1.815, with a sensitivity of 79.9% and a specificity of 84.2%. Serum miR-520f was down-regulated in lung cancer patients, and may be a candidate biomarker for non-invasive screening of the disease.

Low SLCO4C1 expression serves as an independent prognostic predictor in lung cancer

“…In the current investigation, ROC curve analysis demonstrates SLCO4C1's high effectiveness in diagnosing lung cancer, particularly in advanced stages. Comparable diagnostic markers, such as miR-520f and SHOX2 gene promoter hypermethylation, have shown signi cant AUCs in previous studies [25][26][27]. SLCO4C1, therefore, holds considerable potential as a diagnostic biomarker for lung cancer.…”

Circulating miR-106b-5p serves as a diagnostic biomarker for asymptomatic carotid artery stenosis and predicts the occurrence of cerebral ischemic events

“…21 In human cancers, several miRNAs have been identified to be candidate biomarkers for noninvasive screening, such as miR-520f, miR-1290, and miR-21. [22][23][24] Recent researches suggest the potential role of several miRNAs in the pathogenesis of CAS, which may be involved in the evolution of carotid plaque toward growth, instability, and rupture. 25 Another study has compared miRNA expression profiles in atherosclerotic plaques from human carotid arteries and healthy arteries, and several miRNAs are identified to be aberrantly expressed in plaque tissue and associated monocytes.…”

Multiplexed biosensor for point-of-care COVID-19 monitoring: CRISPR-powered unamplified RNA diagnostics and protein-based therapeutic drug management

“…If this measurement results in a signal of the maximum amplitude, we conclude that (i) the subject is not infected with SARS-CoV-1 and (ii) that none of the reagents are RNase contaminated. The positive control speaks to the general performance of the bioassay: in this case it employs a crRNA designed to target synthetic microRNA-520f (miR-520f, associated with proliferation of lung and gastric cancer cells 39,40 ), which is added at a concentration high enough to completely eliminate the amperometric signal. These oligonucleotides could, however, be replaced by any other experimentally validated crRNA-target-pair, with a known amperometric readout that can be correlated to the utilized concentrations.…”